Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash from Operations (2016 - 2025)

Marimed (MRMD) has disclosed Cash from Operations for 13 consecutive years, with 2676000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 233.25% to 2676000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 3853000.0, a 63.07% decrease, with the full-year FY2024 number at 6785000.0, down 14.22% from a year prior.
  • Cash from Operations was 2676000.0 for Q3 2025 at Marimed, up from 297000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 10833000.0 in Q2 2021 to a low of 6261000.0 in Q2 2022.
  • A 5-year average of 3269842.11 and a median of 3185000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 1760.26% in 2021, then plummeted 157.8% in 2022.
  • Marimed's Cash from Operations stood at 7607000.0 in 2021, then plummeted by 77.17% to 1737000.0 in 2022, then surged by 86.18% to 3234000.0 in 2023, then plummeted by 112.77% to 413000.0 in 2024, then skyrocketed by 747.94% to 2676000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Cash from Operations are 2676000.0 (Q3 2025), 297000.0 (Q2 2025), and 1293000.0 (Q1 2025).